These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 9291446)

  • 21. Implantable defibrillators and antiarrhythmic drugs in patients at risk for lethal arrhythmias.
    Zivin A; Bardy GH
    Am J Cardiol; 1999 Nov; 84(9A):63R-68R. PubMed ID: 10568662
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Drugs versus devices in controlling ventricular tachycardia, ventricular fibrillation, and recurrent cardiac arrest.
    Haverkamp W; Eckardt L; Borggrefe M; Breithardt G
    Am J Cardiol; 1997 Oct; 80(8A):67G-73G. PubMed ID: 9354413
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Factors predisposing to ventricular tachyarrhythmia leading to appropriate ICD intervention in patients with coronary artery disease or non-ischaemic dilated cardiomyopathy.
    Lelakowski J; Piekarz J; Rydlewska A; Majewski J; Senderek T; Ząbek A; Małecka B
    Kardiol Pol; 2012; 70(12):1264-75. PubMed ID: 23264245
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antiarrhythmic therapies for the prevention of sudden cardiac death.
    McAlister FA; Teo KK
    Drugs; 1997 Aug; 54(2):235-52. PubMed ID: 9257080
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Class III drugs and congestive heart failure: focus on the congestive heart failure-survival trial of antiarrhythmic therapy.
    Singh SN; Fletcher RD
    Am J Cardiol; 1999 Nov; 84(9A):103R-108R. PubMed ID: 10568668
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Drugs or implantable cardioverter-defibrillators in patients with poor left ventricular function?
    Block M; Hammel D; Böcker D; Borggrefe M; Breithardt G
    Am J Cardiol; 1996 Sep; 78(5A):62-8. PubMed ID: 8820838
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A randomized study of the prevention of sudden death in patients with coronary artery disease. Multicenter Unsustained Tachycardia Trial Investigators.
    Buxton AE; Lee KL; Fisher JD; Josephson ME; Prystowsky EN; Hafley G
    N Engl J Med; 1999 Dec; 341(25):1882-90. PubMed ID: 10601507
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evidence-based medicine and the implantable defibrillator.
    Fogoros RN
    Curr Cardiol Rep; 1999 Jul; 1(2):135-41. PubMed ID: 10980833
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Do we need a randomized trial of defibrillator therapy in every subset of patients with increased risk of sudden death?
    Exner DV; Klein GJ
    J Cardiovasc Electrophysiol; 2003 Jun; 14(6):574-7. PubMed ID: 12875415
    [No Abstract]   [Full Text] [Related]  

  • 30. Ventricular tachycardia and sudden cardiac death.
    Reddy PC; Tandon N; Stafford PR
    J La State Med Soc; 1999 May; 151(5):281-7. PubMed ID: 10363484
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Introduction: primary prevention against sudden cardiac death.
    Waldo AL; Weisfeldt ML
    Am J Cardiol; 1997 Sep; 80(5B):1F-2F. PubMed ID: 9291443
    [No Abstract]   [Full Text] [Related]  

  • 32. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators.
    Moss AJ; Hall WJ; Cannom DS; Daubert JP; Higgins SL; Klein H; Levine JH; Saksena S; Waldo AL; Wilber D; Brown MW; Heo M
    N Engl J Med; 1996 Dec; 335(26):1933-40. PubMed ID: 8960472
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Determinants of patient survival rate after implantation of a cardioverter-defibrillator without resynchronisation capability.
    Lelakowski J; Piekarz J; Rydlewska A; Majewski J; Senderek T; Ząbek A; Małecka B
    Kardiol Pol; 2012; 70(11):1099-110. PubMed ID: 23180517
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Should survivors of myocardial infarction with low ejection fraction be routinely referred to arrhythmia specialists?
    Stevenson WG; Ridker PM
    JAMA; 1996 Aug; 276(6):481-5. PubMed ID: 8691557
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical criteria for predicting benefit of ICD/PM in post myocardial infarction patients: an AVID and CAST analysis.
    Hallstrom AP; Wyse DG; McAnulty J; ;
    J Interv Card Electrophysiol; 2008 Dec; 23(3):159-66. PubMed ID: 18810620
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and safety of celivarone, with amiodarone as calibrator, in patients with an implantable cardioverter-defibrillator for prevention of implantable cardioverter-defibrillator interventions or death: the ALPHEE study.
    Kowey PR; Crijns HJ; Aliot EM; Capucci A; Kulakowski P; Radzik D; Roy D; Connolly SJ; Hohnloser SH;
    Circulation; 2011 Dec; 124(24):2649-60. PubMed ID: 22082672
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The role of the implantable cardioverter-defibrillator for prevention of sudden cardiac death.
    Josephson ME; Callans DJ; Buxton AE
    Ann Intern Med; 2000 Dec; 133(11):901-10. PubMed ID: 11103061
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Implantable defibrillators. Sudden death: high risk].
    Lellouche D; Pujadas-Berthault P; Elbaz N
    Presse Med; 2001 May 5-12; 30(17):867-70. PubMed ID: 11402944
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Why the antiarrhythmics versus implantable defibrillator (AVID) trial sets the wrong precedent.
    Fogoros RN
    Am J Cardiol; 1997 Sep; 80(6):762-5. PubMed ID: 9315584
    [No Abstract]   [Full Text] [Related]  

  • 40. Treatment and prevention of sudden cardiac death: effect of recent clinical trials.
    Goldberger JJ
    Arch Intern Med; 1999 Jun; 159(12):1281-7. PubMed ID: 10386504
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.